Zentalis Pharmaceuticals, Inc.ZNTLNASDAQ
Loading
P/E Ratio: Premium ValuationElevated
Percentile Rank100
Studio
Year-over-Year Change

Price-to-earnings ratio

Latest
-1.30
↑ 90% vs avg
Percentile
P100
Near historical high
Streak
3 yr
Consecutive growthElevated
Average
-12.57
Historical baseline
PeriodValueYoY Change
2024-1.30+61.7%
2023-3.39+24.6%
2022-4.50+80.1%
2021-22.61-25.0%
2020-18.09+0.8%
2019-18.23+8.3%
2018-19.89-